Updated:
Accuray
Accuray makes CyberKnife and Radixact robotic radiation therapy systems, installed in thousands of cancer centers worldwide.
Accuray
Accuray was founded in 1990 as a spinout from Stanford University, commercializing the CyberKnife robotic radiosurgery system invented by neurosurgeon John Adler. The company went public in 2007 and acquired TomoTherapy in 2011, adding helical image-guided radiation therapy to its portfolio. While the founding wealth origin is institutional venture funding rather than a single family's liquidity event, the company's origins trace to a deep academic lineage in stereotactic radiosurgery. The firm's product strategy rests on two cleared platforms: the CyberKnife S7, a robotic linear accelerator mounted on a six-axis arm that tracks tumor motion in real time during treatment, and the Radixact System, the TomoTherapy successor that delivers helical intensity-modulated radiation therapy. Both systems address the same clinical end-markets — thoracic, prostate, brain, spine, liver, and pancreatic tumors — but compete differently. CyberKnife leads in stereotactic radiosurgery, where precise targeting of small lesions matters most. Radixact competes in the broader adaptive radiotherapy segment against Varian's Halcyon and Ethos systems and Elekta's Unity MR-linac. Accuray's geographic revenue split is predominantly North America and EMEA, with a growing installed base in China and Japan through distribution partnerships and regulatory clearances. Accuray has approximately 1,000 employees and maintains manufacturing and R&D operations in Sunnyvale, California, and Madison, Wisconsin, with regional offices in Switzerland and Japan. The company has no adjacent investment vehicles, philanthropic foundations, or club-deal structures — it operates as a pure-play public medical device manufacturer listed on Nasdaq under ARRY. In July 2023, the firm received China NMPA clearance for its VitalHold breast cancer treatment package on the Radixact System, expanding the clinical utility of its installed base in a key growth market (per the firm, July 2023). Accuray's structural differentiator lies in its focus on the radiotherapy market's most technically demanding niches where robotic tracking and non-coplanar beam delivery create a clinical moat. Unlike full-spectrum oncology solutions from Varian (Siemens Healthineers) or Elekta, Accuray does not sell imaging equipment, proton therapy, or software-only solutions — it bets entirely on precision delivery. This makes the company a natural M&A candidate in industry consolidation cycles, though it has remained independent for over two decades.
General information
Firm type
Asset Manager
Year founded
1990
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Sunnyvale
Corporate office
Sunnyvale, CA, United States
Additional offices
Madison, WI · Morges, Switzerland · Tokyo, Japan
Principals
Suzanne Winter
President & CEO
Ali Pervaiz
Senior Vice President, Chief Financial Officer
Sandeep Chawla
Senior Vice President, Chief Marketing, Strategy & Business Development Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Accuray?
As a publicly traded medical device company, capital allocation decisions are made by CEO Suzanne Winter and CFO Ali Pervaiz, subject to board oversight. The company does not operate as a family office or investment firm — its capital deployment goes into internal R&D, manufacturing operations, and clinical evidence-building, not external portfolio investments. Major strategic moves, such as the TomoTherapy acquisition in 2011, require board approval and shareholder communication.
How does Accuray's business model differ from a family office or investment manager?
Accuray is an operating company, not a capital allocator. It manufactures and sells medical devices — specifically robotic radiation therapy systems — to hospitals and cancer centers. Revenue comes from equipment sales, service contracts, and consumables. There is no investment portfolio, no co-investment club, and no discretionary capital managed for third parties. Investors access Accuray by purchasing shares on Nasdaq (ARRY), not through subscriptions or fund commitments.
What is Accuray's competitive position in the radiation oncology market?
Accuray competes in a market dominated by Varian, a Siemens Healthineers company holding roughly 50% global share, and Elekta, with approximately 30%. Accuray and smaller firms like ViewRay split the remainder. Accuray differentiates through robotic, non-coplanar beam delivery for stereotactic radiosurgery — a niche where precision requirements favor dedicated platforms over general-purpose linear accelerators. The company has over 1,000 systems installed worldwide.
Does Accuray have any related investment vehicles or operating subsidiaries?
No. Accuray's corporate structure is straightforward — one publicly traded entity with international subsidiaries in Europe and Asia for sales and service. There are no affiliated investment funds, philanthropic foundations, co-investment vehicles, or operating businesses outside the radiation oncology core. The company's predecessor relationship with Stanford is a technology lineage, not an ongoing ownership or governance link.
Where does Accuray's underlying capital come from?
Accuray's original funding came from venture capital, including investments from CMEA Ventures and other life sciences VCs during its pre-IPO years. The company raised $233 million in its 2007 IPO and has since operated as a publicly financed entity. There is no single-family wealth origin or founding endowment — it is a classic Silicon Valley venture-backed technology company applied to medical devices.
How is Accuray positioned around AI and automation in radiation oncology?
Accuray integrates automated motion tracking, AI-driven treatment planning, and adaptive delivery into its CyberKnife and Radixact platforms. The Synchrony technology on CyberKnife tracks tumor movement in real time during breathing without requiring breath-holds or fiducial markers in some indications. The company competes on automation speed — Radixact treatment times and plan adaptation occupy a specific value proposition against Varian's Ethos and Elekta's Unity systems.
What is Accuray's known posture on acquisitions or being acquired?
Accuray has been both an acquirer — purchasing TomoTherapy for approximately $277 million in 2011 — and a perennial subject of M&A speculation as consolidation reshapes radiotherapy (Siemens acquired Varian for $16.4 billion in 2021). The company has remained independent, with management focused on margin expansion and installed-base growth rather than positioning for sale. Publicly, the firm communicates organic growth priorities with selective technology licensing or tuck-in acquisitions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: